Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0080u-biodesix-bdx-xl2-lung-nodule-risk-assay
    Ask Trek AI about this page

    CPT 0080U: BDX–XL2 Blood Biomarker Test for Lung Nodules

    CPT code 0080U is a Proprietary Laboratory Analyses (PLA) code for the Biodesix® BDX–XL2 blood test that measures two plasma proteins and combines those results with five clinical risk factors in an algorithm to estimate the likelihood that a pulmonary nodule is benign or malignant; this service is a laboratory-based molecular diagnostic algorithm performed on blood plasma and is typically provided by the performing laboratory or a reference diagnostic laboratory (outpatient or ambulatory laboratory setting).

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0080U policy alerts

    Get alerted when payer policies referencing 0080U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 67-year-old current or former smoker presents to a pulmonology clinic after a routine chest CT performed for screening or evaluation of respiratory symptoms identifies a solitary pulmonary nodule measuring 8–30 mm. The chest CT report documents nodule size, location, margins, and any prior imaging comparison. The clinician considers noninvasive risk stratification to avoid unnecessary invasive diagnostic procedures. The clinician orders the proprietary BDX–XL2 blood-based test (Proprietary Laboratory Analyses code 0080U) from Biodesix, Inc. to measure two plasma proteins and combine those biomarker results with five clinical risk factors via the test algorithm to estimate the probability that the nodule is benign versus malignant.

    Typical workflow:

    • The clinician documents the indication (suspicious pulmonary nodule) and relevant risk factors (age, smoking history, nodule size, nodule location, and presence/absence of previous cancer history) in the chart.

    • A phlebotomy encounter is scheduled at an outpatient lab or hospital outpatient drawing station (Typical Site of Service: outpatient laboratory or hospital outpatient phlebotomy). A general internal medicine, pulmonology, thoracic surgery, or oncology provider orders the test.

    • Blood is drawn, processed per Biodesix specimen requirements, and shipped to the performing laboratory for analysis. The laboratory runs the proprietary assay and returns a report with the combined algorithmic risk score and interpretive guidance to the ordering provider.

    • The ordering provider reviews results and integrates the risk estimate with imaging findings and clinical judgment to decide surveillance with serial CT, PET/CT, or pursue biopsy or resection. Documentation should link the test order to the pulmonary nodule diagnosis and record the result in the medical record.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0080UBDX–XL2 test (Biodesix) — blood plasma assay combining two protein biomarkers with clinical risk factors to estimate likelihood a lung nodule is benign or malignantPrimary proprietary laboratory test being ordered for noninvasive risk stratification of indeterminate pulmonary nodules.
    71045Radiologic examination, chest, single view, frontalOften performed as an initial imaging study in workup prior to CT and may be part of baseline assessment.
    71250Computed tomography, thorax; without contrast materialChest CT is the primary imaging modality used to detect and characterize pulmonary nodules prior to ordering biomarker testing.
    78815Positron emission tomography (PET) with concurrently acquired CT for attenuation correction and anatomical localization, whole bodyPET/CT is commonly used after biomarker testing if risk is elevated to further evaluate metabolic activity of a nodule.

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207L00000X
    2084P0800X
    363A00000X
    221700000X
    1835E0208X
    2085R0205X
    2084S0012X
    3336H0001X

    Related ICD-10-CM Codes

    23 rows

    ICD-10-CM CodeDescription
    C34.2Malignant neoplasm of middle lobe, bronchus or lung
    C34.81Malignant neoplasm of overlapping sites of right bronchus and lung
    C34.82Malignant neoplasm of overlapping sites of left bronchus and lung
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung
    D02.20Carcinoma in situ of unspecified bronchus and lung
    D02.21Carcinoma in situ of right bronchus and lung
    D02.22Carcinoma in situ of left bronchus and lung
    D38.1Neoplasm of uncertain behavior of trachea, bronchus and lung
    J44.9Chronic obstructive pulmonary disease, unspecified
    J45.909Unspecified asthma, uncomplicated

    Showing 1–10 of 23

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancerblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    32405
    Biopsy, lung or mediastinum, percutaneous needle; with imaging guidance
    Invasive tissue sampling that may be performed if noninvasive risk stratification suggests high likelihood of malignancy.
    88305Pathology examination, surgical specimen, gross and microscopic examinationPathology code used to report evaluation of biopsy or resection specimens obtained following imaging and risk assessment.